Bellerophon provides clinical program update and reports first quarter 2022 financial results

Warren, n.j., may 11, 2022 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended march 31, 2022.

BLPH Ratings Summary

BLPH Quant Ranking